NOBLE: Tc-99m-iPSMA SPECT shows promising results
Promising results following the initial experience using Tc-99m-iPSMA led by [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]
PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC
Urology Times Journal, Jason M. Broderick - April 15, 2021 [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]
Real-world data analysis of efficacy and survival after Lu-177 PSMA
177Lu-PSMA radioligand therapy provides a significant response rate with a [...]
PSMA Lu-177 x Ac-225
Available since 2015, the treatment of patients with metastatic castration-resistant [...]
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T [...]
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer
PubMed, July 23, 2020 Despite the success of several standards [...]